Gain detailed insights into the trading activity of Congress members for Vaxcyte on our government trades page. Stay updated on how elected officials are investing in PCVX.

Vaxcyte - Government Trades

Vaxcyte

Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-24, VAX-A1, and VAX-PG.

Xpeng g6 SUV

Large Cap

News

Movers

ABBV

CACI

LDOS

MNDY

MPWR

MRNA

NVDA

PCVX

SMCI

XPEV

10 worst performing large-cap stocks last week: MPWR, SMCI, MRNA, LDOS, MNDY, PCVX, BAH, ABBV, CACI, XPEV. Check if they&#39;re in your portfolio.

Super Micro Computer, Moderna And XPeng Were Among Top 10 Large Cap Stocks Losing Big Last Week (November 11-15): Check Out Other Losers

movers image

Intraday Update

Markets

AAOI

AGMH

AIXI

AMAT

APDN

ASST

ATPC

AUUD

AVTX

BNRG

Chemomab Therapeutics Ltd. - American Depositary Shares

CMMB

CNFR

FEDU

GERN

INTC

IOBT

KROS

LITB

MNOV

MRVL

MSGM

NVAX

NVCR

NVMI

PSNY

QNTM

RXRX

SGRP

SHLS

SIFY

SLXN

STRL

TCBP

WINT

Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

Trading Ideas

AIRJ

BBIO

BILI

VERA

Vaxcyte, Shoals Technologies, Polestar Automotive, Applied Optoelectronics And Other Big Stocks Moving Higher On Tuesday

Research And Vaccine Development

Biotech

Health Care

General

Vaxcyte announced positive topline results from its Phase 1/2 study of VAX-31, a 31-valent pneumococcal conjugate vaccine candidate, showing strong immune responses and safety comparable to Pfizer&#39;s Prevnar 20. VAX-31 will advance to Phase 3 trials with plans for a pivotal study by mid-2025.

Bacterial Infections Vaccine Developer Vaxcyte&#39;s Pneumococcal Shot Shows Promise in Mid-Stage Trial, Stock Shoots Higher

Health care cost illustration

Analyst Color

Equities

Price Target

Reiteration

Analyst Ratings

The global PCV market, valued at ~$8 billion annually, is poised for significant growth, estimated to reach ~$12 billion soon. Market dynamics are shifting towards adults, potentially doubling with the US discussing vaccination age reduction. Prevnar20 dominates with 97% market share in adults, but Vaxcyte&#39;s advanced conjugate capabilities present a competitive advantage.

Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck&#39;s Pneumococcal Shots - Analyst Says

ACAD

ASAN

ORCL

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Oracle To Rally Around 40%? Here Are 10 Top Analyst Forecasts For Tuesday

Small Cap

PHAT

Needham analyst Joseph Stringer reiterated a Buy rating on Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT), 

&#34;Top Pick for 2024&#34;: Analyst Bullish On Phathom Pharmaceuticals On Voquezna Launch In Erosive GERD, Projecting $55.6M In Sales

Initiation

Mizuho Securities initiated coverage on Vaxcyte Inc (NASDAQ: PCVX), a vaccine company targeting bacterial infectious diseases (primarily for disease prevention). 

Vaccine Player Vaxcyte Can Potentially Disrupt Pfizer&#39;s 20-Plus-Year Near Monopoly, Says Analyst

Where Is The Current Bull Market? Scan Of Stocks Gaining Over 20% Over The Past Week Almost Exclusively Yields Biotech Names

ETFs

CRSP

LEGN

MDGL

RVMD

VTYX

Where is the current bull market? All indications would be that it&#39;s in biotech! The broader market is not really moving. There have been plenty of attention-grabbing headlines, and earnings season is upon us, yet the S&amp;P 500 has been largely stagnant in recent trading sessions.

Offerings

After-Hours Center

Vaxcyte Inc (NASDAQ: PCVX) shares are trading lower in Monday&#39;s after-hours session after the vaccine company announced the commencement of a 

Why Vaxcyte Stock Is Sliding After Hours

Vaxcyte Inc

Citigroup analyst Jon Tower maintains Brinker International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EAT#NYSE">EAT</a>) with a Neutral and raises the price target from $166 to $185.

Citigroup Maintains Neutral on Brinker International, Raises Price Target to $185

Citigroup analyst Scott Gruber maintains Seadrill (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SDRL#NYSE">SDRL</a>) with a Buy and lowers the price target from $50 to $46.

SDRL

Citigroup Maintains Buy on Seadrill, Lowers Price Target to $46

American Express (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>) has outperformed the market over the past 5 years by 6.37% on an annualized basis producing an average annual return of 19.32%. Currently, American Express has a market capitalization of $223.90 billion. 
Buying $100 In AXP: If an investor had bought $100 of AXP stock 5 years ago, it would be worth $243.47 today based on a price of $318.95 for AXP at the time of writing.
<h3>American Express's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738278015_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning American Express Stock In The Last 5 Years

Citigroup analyst Scott Gruber maintains Valaris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VAL#NYSE">VAL</a>) with a Neutral and raises the price target from $47 to $48.

Citigroup Maintains Neutral on Valaris, Raises Price Target to $48

Citigroup analyst Asiya Merchant maintains Western Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) with a Buy and lowers the price target from $82 to $80.

Citigroup Maintains Buy on Western Digital, Lowers Price Target to $80

Citigroup analyst Patrick Donnelly maintains Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Buy and lowers the price target from $285 to $265.

Citigroup Maintains Buy on Danaher, Lowers Price Target to $265

Citigroup analyst George Choi maintains Las Vegas Sands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LVS#NYSE">LVS</a>) with a Buy and raises the price target from $64.5 to $67.

Citigroup Maintains Buy on Las Vegas Sands, Raises Price Target to $67

Maxim Group analyst Jason McCarthy maintains Alterity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHE#NASDAQ">ATHE</a>) with a Buy and raises the price target from $8 to $12.

Alterity Therapeutics Limited - American Depositary Shares

ATHE

Maxim Group Maintains Buy on Alterity Therapeutics, Raises Price Target to $12

Earnings

HFBL

CORRECTION: Home Federal Bancorp Q2 EPS $0.33, Flat YoY

Cheniere Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNG#NYSE">LNG</a>) has outperformed the market over the past 5 years by 18.24% on an annualized basis producing an average annual return of 31.2%. Currently, Cheniere Energy has a market capitalization of $51.65 billion. 
Buying $1000 In LNG: If an investor had bought $1000 of LNG stock 5 years ago, it would be worth $3,918.96 today based on a price of $230.20 for LNG at the time of writing.
<h3>Cheniere Energy's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738277138_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Cheniere Energy 5 Years Ago Would Be Worth This Much Today

Shares of Common Stock are expected to begin trading on the New York Stock Exchange under the ticker symbol "INR." The offering is expected to close on February 3, 2025, subject to customary closing conditions.

IPOs

Infinity Natural Resources Prices Public Offering Of 13.25M Shares Of Class A Common Stock At $20.00 Per Share

Maxim Group analyst Allen Klee initiates coverage on Orangekloud Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORKT#NASDAQ">ORKT</a>) with a Buy rating and announces Price Target of $5.

ORKT

Maxim Group Initiates Coverage On Orangekloud Technology with Buy Rating, Announces Price Target of $5

Walgreens Boots Alliance Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) shares are falling in extended trading Thursday after the company <a href="https://www.benzinga.com/pressreleases/25/01/b43355741/walgreens-boots-alliance-suspends-quarterly-dividend-as-company-continues-disciplined-execution-ag">suspended its quarterly dividend</a>.
What Happened: After the market close on Thursday, Walgreens announced its board is suspending its cash dividend as management continues to evaluate its capital allocation policy as part of a longer-term turnaround strategy.
The suspended dividend is expected to help strengthen the company&#8217;s balance sheet by reducing debt over time and improving free cash flow.
&#8220;The company&#8217;s cash needs over the next several years, including with respect to litigation and debt refinancing, were important considerations as part of the decision to suspend the dividend,&#8221; the company said. 
&#8220;WBA leadership remains focused on successfully executing against its strategic priorities and maintaining financial discipline, which it believes will deliver sustained value creation over the long term.&#8221;
<h1 class="wp-block-heading">How To Buy WBA Stock</h1>
By now you're likely curious about how to participate in the market for Walgreens — be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share. 
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading — either way it allows you to profit off of the share price decline.
WBA Price Action: <a href="http://benzinga.com/quote/wba">Walgreens shares</a> were down 7.77% after-hours, trading at $10.52 at the time of publication Thursday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/01/43355688/apple-q1-earnings-revenue-beat-eps-beat-iphone-sales-slip-installed-base-climbs-to-all-time-high-our-best-quarter-ever">Apple Q1 Earnings: Revenue Beat, EPS Beat, iPhone Sales Slip, Installed Base Climbs To All-Time High — &#8216;Our Best Quarter Ever&#8217;</a></li>
</ul>
Photo: Courtesy of Walgreens Boots Alliance.

Dividends

Walgreens Boots Alliance Shares Slide As Board Suspends Dividend

For the quarter ended December 31, 2024, the company reported a net loss of $2.0 million, or $0.03 per diluted common share, compared to net income of $0.9 million, or $0.01 per diluted common share, for the quarter ended September 30, 2024, and a net loss of $5.8 million for the fourth quarter of 2023.&nbsp;

BRBS

Blue Ridge Bankshares Q4 EPS $(0.03), Says Regulatory Remediation Efforts On Track

Lake Street analyst Eric Martinuzzi maintains Extreme Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXTR#NASDAQ">EXTR</a>) with a Hold and raises the price target from $15 to $16.

EXTR

Lake Street Maintains Hold on Extreme Networks, Raises Price Target to $16

Boot Barn Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOOT#NYSE">BOOT</a>) reported its third-quarter financial results after Thursday's closing bell. Here's a look at the<a href="https://www.benzinga.com/pressreleases/25/01/b43352747/boot-barn-holdings-inc-announces-third-quarter-fiscal-year-2025-financial-results"> details from the report.&nbsp;</a>
The Details:&nbsp;Boot Barn reported earnings of $2.43 per share, beating the $2.29 estimate. Quarterly revenue came in at $608.17 million, beating the $607.01 million estimate.
Same-store sales increased 8.6% compared to the prior-year period, comprised of an increase of 8.2% in retail store same-store sales and an increase of 11.1% in e-commerce same-store sales. The company opened 13 new stores, bringing its total store count to 438 as of the quarter end.
Read Next: <a href="https://www.benzinga.com/general/travel/25/01/43343648/all-60-passengers-4-crew-members-onboard-american-airlines-jet-feared-dead-after-midair-collision-official-says">64 Killed In American Airlines Midair Collision Near D.C., Worst US Air Disaster Since 2001&nbsp;</a>
&#8220;I want to thank the entire Boot Barn team for their excellent execution and dedication during a busy holiday season, which resulted in strong third-quarter results and earnings per diluted share above the high end of our guidance range. The strength we saw in the business was once again driven by broad-based growth across all major merchandise categories, channels and geographies, resulting in a consolidated same-store sales increase of 8.6%,&#8221; said John Hazen, Interim CEO.
&#8220;We also grew total sales 16.9% compared to the prior-year period, driven in part by the 13 new stores we opened in the third quarter and the 39 new stores we have opened year-to-date through our third fiscal quarter,&#8221; Hazen added. 
Outlook:&nbsp;Boot Barn raised its fiscal 2025 GAAP EPS guidance from a range of&nbsp;$5.30 to $5.60 to a range of $5.81 to $5.90, versus the&nbsp;$5.76&nbsp;estimate, and raised its fiscal 2025 sales guidance from a range of $1.87 billion to $1.91 billion to&nbsp;a range of $1.91 billion to $1.92 billion, versus the $1.91 billion estimate. 
BOOT Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Boot Barn Holdings shares are down 6.60% after-hours at $163 on Thursday.  
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/01/43320124/microsoft-shares-slide-after-q2-results-cloud-revenue-misses-expectations-details">Microsoft Shares Slide After Q2 Results, Cloud Revenue Misses Expectations: Details</a>&nbsp;</li>
</ul>
Photo: Courtesy of Boot Barn Holdings, Inc.

BOOT

Boot Barn Stock Falls After Q3 Report: What To Know

Loop Capital analyst Alton Stump maintains Silgan Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLGN#NYSE">SLGN</a>) with a Buy and raises the price target from $70 to $75.

SLGN

Loop Capital Maintains Buy on Silgan Hldgs, Raises Price Target to $75

Coherent (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COHR#NYSE">COHR</a>) has outperformed the market over the past 5 years by 7.19% on an annualized basis producing an average annual return of 20.15%. Currently, Coherent has a market capitalization of $14.03 billion. 
Buying $1000 In COHR: If an investor had bought $1000 of COHR stock 5 years ago, it would be worth $2,656.40 today based on a price of $90.71 for COHR at the time of writing.
<h3>Coherent's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738276219_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

COHR

If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today

Barclays analyst George Wang maintains Celestica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) with a Overweight and raises the price target from $91 to $139.

Barclays Maintains Overweight on Celestica, Raises Price Target to $139

As AI develops, a shift in expectations for electricity demand is becoming more evident. The emergence of Chinese artificial intelligence company DeepSeek has led to uncertainty about future electricity consumption, impacting <a href="https://www.benzinga.com/topic/utilities">utility and power stocks. </a>
Investors in the traditional power and utilities sector are facing uncertainty after riding last year's wave of soaring demand projections. The rapid expansion of energy-intensive data centers—critical to AI and other tech innovations—had fueled a surge in power stocks. However, the question mark on this forecast has brought <a href="https://www.benzinga.com/etfs">power-focused ETFs</a> back into the limelight for the wrong reasons. Although experts believe this is most likely a temporary panic, here are 3 ETFs that may be less sensitive to short-term chaos:
Utilities Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) 
XLU provides exposure to major U.S. utility companies, including American Electric Power Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEP#NASDAQ">AEP</a>) and Southern Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SO#NYSE">SO</a>). The ETF is a popular choice for investors seeking stable returns and dividend income from regulated utilities, which are less sensitive to short-term market disruptions. The expense ratio is 0.09%.
Invesco S&amp;P 500 Equal Weight Utilities ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSPU#NYSE">RSPU</a>)
Traditional utility ETFs are market-cap weighted. On the contrary, this ETF assigns equal weight to its holdings, which allows the investor to spread out risks. It includes companies involved in electricity production, transmission, and renewable energy, making it a potential hedge against volatility in the energy sector. The expense ratio is 0.4%.
First Trust NASDAQ Clean Edge Smart Grid Infrastructure Index Fund (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRID#NASDAQ">GRID</a>)
GRID focuses on companies engaged in smart grid technology, electrification infrastructure, and power transmission. As the U.S. accelerates its shift to renewable energy, investments in smart grids and electricity storage could benefit from long-term demand growth, regardless of AI-related fluctuations.
Also Read: <a href="https://www.benzinga.com/etfs/sector-etfs/25/01/43350500/deepseek-shakes-up-ai-stocks-3-healthcare-tech-etfs-offer-stability-innovation">DeepSeek Shakes Up AI Stocks: 3 Healthcare Tech ETFs Offer Stability, Innovation</a>
<h3 class="wp-block-heading">The AI Revolution and Its Impact on Power Demand</h3>
The DeepSeek issue challenges long-standing projections about electricity demand driven by AI data centers. DeepSeek&#8217;s AI model, reportedly uses &#8220;10 to 40 times less energy&#8221; than similar U.S. models, according to a <a href="https://www.eenews.net/articles/game-changer-what-deepseek-ai-means-for-electricity/">report </a>by E&amp;E News. 
Utilities and natural gas companies, which had been soaring on expectations of rising AI-driven electricity demand, suffered steep losses. According to Reuters, independent power provider Constellation Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>) plunged by about 20%, Vistra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>) dropped 30%, and Talen Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLN#NASDAQ">TLN</a>) fell 22% after news of DeepSeek&#8217;s advancements hit.
While some experts believe this could reset expectations for power growth, others argue that broader electrification trends, including U.S. manufacturing expansion and cryptocurrency mining, will keep electricity demand high. 
&#8220;Overall electricity demand is still going to surge because other major drivers — particularly U.S. manufacturing and cryptocurrency — are not going to be affected by DeepSeek,&#8221; said Betsy Soehren Jones, managing director at West Monroe, as reported by E&amp;E News.
DeepSeek&#8217;s accomplishment could even cast doubt on nuclear power demand, which tech companies see as a key source of clean energy for AI development. Investors have expected high premiums for nuclear power, over $100/MWh, but new efficiency gains may change that, Jefferies said in a client note, <a href="https://www.argusmedia.com/en/news-and-insights/latest-market-news/2652323-deepseek-undermines-ai-power-demand-forecasts">according </a>to Argus Media. 
Lower AI data center power demand could also weaken support for next-generation small modular reactors (SMRs), backed by companies like Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) and Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>).
Also Read: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/43267966/deepseeks-low-cost-model-reshapes-ai-landscape-experts-predict-shift-to-application-layer">DeepSeek&#8217;s Low-Cost Model Reshapes AI Landscape: Experts Predict Shift To &#8216;Application Layer&#8217;</a>
<h3 class="wp-block-heading">What BofA Says About the Power and Utility Sector</h3>
A recent Bank of America (BofA) report suggests that the power and utility sector remains resilient despite the short-term market reaction to DeepSeek&#8217;s AI model. The report maintains a Buy rating on Constellation Energy with a revised price target of $366 and a Neutral rating on Vistra with a target of $183.
BofA analysts see the sell-off as an overreaction and expect data center demand to stay strong once the turbulence subsides.
The report describes DeepSeek as "more evolutionary than revolutionary" and that AI-driven data centers will continue to drive power consumption.
Additionally, BofA notes that supply and demand pressures in the energy market remain tight due to industrial expansion and electrification. The need for stable energy sources like nuclear power remains essential.
<h3 class="wp-block-heading">Will DeepSeek Really Change The Power Scenario?</h3>
While DeepSeek's AI model has introduced uncertainty in the short term, some analysts believe the sell-off in power stocks may be &#8220;short-sighted and short-lived,&#8221; as energy economist Ed Hirs noted, per a Reuters report. Even with more efficient AI models, demand for electricity is likely to rise due to continued digitalization and electrification.
All said, despite the sharp reaction in the market, broader trends in electrification and technology-driven growth suggest that electricity consumption will keep rising.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/global/25/01/43315374/ai-etfs-in-focus-as-alibaba-challenges-deepseek-with-new-model">AI ETFs In Focus As Alibaba Challenges DeepSeek With New Model</a></li>
</ul>
Photo: Sundry Photography/ Shutterstock.com

Sector ETFs

GOOG

GOOGL

First Trust Nasdaq Clean Edge Smart Grid Infrastructure Index Fund

GRID

MSFT

Invesco S&P 500 Equal Weight Utilities ETF

RSPU

3 ETFs To Navigate Utility Stock Volatility As DeepSeek Challenges Power Demand Forecasts

Financing

Press Releases

Vaxcyte Announces Pricing of $1.3 Billion Public Offering

Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference

Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update

Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs

Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants


Chris JacobsHouse (R-NY)	$1K - $15K	stock	Sale	Jan 20, 2023	Dec 12, 2022	House
Chris JacobsHouse (R-NY)	$1K - $15K	stock	Purchase	Dec 12, 2022	Nov 08, 2022	House

Government Trades

Vaxcyte Inc

top performing PCVX trades

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga